US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 21:13:47 Source:travelViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Messi in and Dybala out in Argentina squad for pre
Next:Ricky Stenhouse punching Kyle Busch could lead to suspension
You may also like
- College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
- Xi congratulates Prabowo Subianto on election as Indonesian president
- Wang wraps up tour of New Zealand, Australia
- Xi hails new chapter of China
- Cannes 2024: Studio Ghibli takes a bow with an honorary Palme d'Or
- China emphasises importance in relations with the UK
- China lodges solemn representations with U.S. over harassment of Chinese visitors
- Green efforts gain more ground
- Jodie Turner